• Invest
    Investment Suite
    Stocks
    Mutual Funds
    Future and Options
    IPO
    Exchange Traded Funds
    Commodity
    Stockcase (Stock Baskets)
    Currency
    Non Convertible Debentures
    Sovereign Gold Bond
    Exclusive
    NRI Account
    Private Client Group
    Features
    SipIt
    MTF
    Investment Suite
    Exclusive
    Features
  • Platform
    Product Suite
    Kotak Neo App & Web
    Nest Trading Terminal
    NEO Trade APIs
    Features and Tools
    MTF
    Securities Accepted as Collateral
    Margin Requirements
    Payoff Analyzer
    Calculators
    SIP Calculator
    Lumpsum Calculator
    Brokerage Calculator
    Margin Calculator
    MTF Calculator
    All Calculators
    Product Suite
    Features and Tools
    Calculators
  • Pricing
  • Research
    Research Calls
    Long Term calls
    Short Term calls
    Intraday calls
    Derivatives calls
    Pick of the week
    Top Monthly Picks
    Research Reports
    Fundamental Research Report
    Technical Research Report
    Derivative Research Report
    Research Calls
    Research Reports
  • Market
    Stocks
    Market Movers
    Large Cap
    Mid Cap
    Small Cap
    Indices
    Nifty 50
    Bank Nifty
    FinNifty
    Nifty Midcap India
    VIX
    All Indian Indices
    Mutual Funds
    SBI Mutual Funds
    HDFC Mutual Funds
    Axis Mutual Funds
    ICICI Prudential Mutual Funds
    Nippon India Mutual Funds
    All AMC's
    IPO
    Upcoming IPO
    Current IPO
    Closed IPO
    Recently Listed IPO
    Stocks
    Indices
    Mutual Funds
    IPO
  • Learn
    Resource
    Market Ready
    Kotak Insights
    Infographic
    Podcast
    Webinars
    Youtube Channel
    Quarterly Results
    Investing Guide
    Demat Account
    Trading Account
    Share Market
    Intraday Trading
    IPO
    Mutual Funds
    Commodities
    Currency
    Futures & Options
    Derivatives
    Margin Trading
    Events
    Budget 2024
    Muhurat Trading
    Share Market Holiday
    Market Outlook 2024
    Resource
    Investing Guide
    Events
  • Partner
    Business Associates
    Fund Expert
    Kotak Connect Plus
    Startup connect
  • Support
    FAQs
    Circulars
    Bulletins
    Contact Us
    Forms Download
    Get your Statement

Akums Drugs and Pharmaceuticals Limited IPO - Unveiling the Company’s Key Strengths

  •  3 min read
  • 0
  • 30 Jul 2024
Akums Drugs and Pharmaceuticals Limited IPO - Unveiling the Company’s Key Strengths

With an issue size of ₹1,856.74 crores, D-street is ready for Akums Drugs and Pharmaceuticals Limited’s initial public offering (IPO) on July 30. The company is the largest India-focussed contract development and manufacturing organisation (CDMO) in terms of revenue, production capacity, and clients served during FY23.
Source: KSL

During FY2024, it had a market share of 30.2% of the Indian domestic CDMO market by value, which increased from 26.7% during FY2021. The company boasts several competitive strengths that make it stand out.
Source: RHP

Strengths of Akum Drugs and Pharmaceuticals Limited

Here are some of the key strengths of the company:

  • Largest CDMO serving the Indian pharmaceutical industry

Akums Drugs and Pharmaceuticals Ltd became the largest CDMO in India during FY23 in terms of clients served, revenue, and production capacity. The company offers a comprehensive range of pharma products and services.

Along with its subsidiaries, as of March 31, 2024, it operates 12 manufacturing units with a cumulative formulations manufacturing capacity aggregating to 49.23 billion units annually. During FY2024, the company had a market share of 30.2% by value in the Indian domestic CDMO market.
Source: RHP

  • Diverse client base with longstanding CDMO relationships

As of March 31, 2024, the company's client base for its CDMO business comprised 1,524 Indian and multinational pharmaceutical and wellness companies, an increase from 1,386 as of March 31, 2022. The firm's client base includes a diverse range of clients, such as pharmaceutical companies, nutraceutical companies, cosmo-derma companies, wellness companies, e-commerce companies, healthcare providers, and central and state government entities.

During FY2024, the company manufactured formulations for 26 of the leading 30 pharmaceutical companies in terms of sales in India. It has benefitted from repeat orders in the past five years from 38 of our 50 largest clients in terms of revenue for its CDMO business, as of March 31, 2024.
Source: RHP

  • Large and rapidly growing R&D capabilities across product portfolio

The company offers differentiated products and services. Its in-house product strategy team conceptualises new formulations based on emerging epidemiological trends, global product approvals and opportunities within the pharmaceutical, wellness, and nutraceutical sectors. As of March 31, 2024, the company operates four dedicated R&D units and engaged 406 R&D scientists across its businesses.

Two of its R&D units have been approved by the Department of Scientific and Industrial Research, Government of India. As of March 31, 2024, the company has obtained 1,448 trademarks across various dosage forms and formulations. Further, as of March 31, 2024, it has procured 927 Drug Controller General of India (DCGI) approvals and five patents.
Source: RHP

  • Strategic presence across the pharmaceutical value chain

Akums presence in the Indian pharmaceutical landscape is augmented by its strong domestic CDMO presence and amplified through its global export initiatives. This gives the company a competitive edge in the industry, allowing it to navigate growth opportunities across multiple markets.

Moreover, its adherence to global regulatory standards reinforces its ability to contribute to global healthcare solutions, expanding its footprint in overseas markets. As of March 31, 2024, it carries out the export of branded formulations and has established a global presence across 65 countries. The company has 289 dossiers under registration.
Source: RHP

Summing it Up

One will have to wait and watch how investors respond to this IPO. The IPO’s lot size is 22, and its price range is Rs 646 to 679 . For exclusive details, go through the company’s red herring prospectus.
Source: KSL

Disclaimer: This article is for informational purposes only and does not constitute financial advice. It is not produced by the desk of the Kotak Securities Research Team, nor is it a report published by the Kotak Securities Research Team. The information presented is compiled from several secondary sources available on the internet and may change over time. Investors should conduct their own research and consult with financial professionals before making any investment decisions. Read the full disclaimer here.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing. Please read the SEBI-prescribed Combined Risk Disclosure Document before investing. Brokerage will not exceed SEBI’s prescribed limit

Did you enjoy this article?

0 people liked this article.

What could we have done to make this article better?

Enjoy Free Demat Account Opening
+91 -

personImage
Enjoy Free Demat Account Opening
+91 -